Zai Lab Limited
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zai Lab Limited is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative medicines for patients in areas of significant unmet medical need, particularly within oncology, autoimmune disorders, infectious diseases, and neuroscience. The company operates primarily in Mainland China and Hong Kong, with a growing global presence. Zai Lab's commercial portfolio features several innovative therapies. Zejula (niraparib) is a once-daily oral PARP 1/2 inhibitor approved for the maintenance treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, including first-line and recurrent platinum-sensitive settings. Optune delivers Tumor Treating Fields, a non-invasive therapy for newly diagnosed and recurrent glioblastoma (GBM). NUZYRA (omadacycline) is a modern tetracycline-class antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Qinlock (ripretinib) is a kinase inhibitor indicated for advanced gastrointestinal stromal tumors (GIST) in adult patients who have received prior treatments. More recently, XACDURO (sulbactam-durlobactam) received approval in China for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Acinetobacter baumannii-calcoaceticus complex isolates. The company also commercializes VYVGART, an FcRn blocker for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) in China, which significantly contributes to its revenue. The company maintains a robust and diverse pipeline of investigational therapies. This includes Odronextamab for various B-cell lymphomas and Repotrectinib (also known as AUGTYRO), a tyrosine kinase inhibitor targeting ROS1 and TRK fusions, with approvals in some markets and a key revenue driver for Zai Lab. Other pipeline assets feature Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated solid tumors, and Bemarituzumab, which has shown promise in gastric and gastroesophageal junction cancer and received FDA Fast Track designation. Zai Lab is also advancing internal research and development programs, such as ZL-1102, a topical anti-IL-17A human nanobody in Phase 2 for chronic plaque psoriasis. Furthermore, KarXT (xanomeline-trospium), an oral M1/M4-preferring muscarinic agonist, is progressing for psychiatric and neurological conditions like schizophrenia, with a New Drug Application accepted in China. The pipeline also includes ZL-1310, a DLL3 antibody-drug conjugate for small cell lung cancer, which has received FDA Fast Track designation and is slated for a pivotal study in late 2025. Zai Lab's revenue model is largely driven by product sales from its commercialized therapies in China, supplemented by collaboration agreements that can include upfront payments, milestones, and royalties. The company, founded in 2013, has headquarters in Shanghai, China, and offices in the United States, pursuing a strategy of leveraging global partnerships to bring innovative medicines to patients in China and beyond, with a focus on addressing high unmet medical needs. Zai Lab reported a total revenue of $0.39 billion in 2024, with a projected path toward profitability by 2025.
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Announces Changes to Senior Leadership Team
Zai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag Attached
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
Zai Lab Q1 Earnings Call Highlights
Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Zai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases Transcript
Zai Lab (NASDAQ:ZLAB) Sees Strong Trading Volume – Still a Buy?
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative
Ying Du Sells 5,576 Shares of Zai Lab (NASDAQ:ZLAB) Stock
Yajing Chen Sells 5,199 Shares of Zai Lab (NASDAQ:ZLAB) Stock
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of “Moderate Buy” by Brokerages